STOCK TITAN

CEO-linked entities report 33.34% Jyong Biotech (MENS) stake via trust

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

Jyong Biotech Ltd. received a major ownership disclosure showing that Perfect Minds Co., Ltd. and related entities beneficially own 25,349,500 ordinary shares, or 33.34% of the company’s ordinary shares, based on 76,027,667 shares outstanding as of April 24, 2026.

Perfect Minds, a Seychelles holding company, directly holds the shares. It is wholly owned by Innovation Global Group Limited, which in turn is owned by The Innovation Trust, for which Unity Trust Limited acts as trustee. Ms. Kuo Fu‑Feng, the issuer’s Chief Executive Officer and Chairwoman, is settlor of the trust and sole director of Perfect Minds and has sole voting and dispositive power over these shares.

The stake was acquired for approximately $5,760,075, funded by Ms. Kuo. The reporting persons state they hold the shares for investment purposes and, aside from what is described, do not currently have additional plans tied to corporate actions listed under Item 4.

Positive

  • None.

Negative

  • None.

Insights

CEO-linked trust structure controls about one-third of Jyong Biotech.

The filing shows entities associated with Ms. Kuo Fu‑Feng beneficially own 25,349,500 ordinary shares, representing 33.34% of Jyong Biotech. The shares are held through Perfect Minds Co., Ltd., its BVI parent Innovation Global Group Limited, and The Innovation Trust.

Although IGGL, The Innovation Trust and Unity Trust Limited report no voting power, Ms. Kuo has sole voting and dispositive power via Perfect Minds. This consolidates significant influence in one executive-linked holder, aligning management and ownership.

The stake was acquired for about $5,760,075, funded by Ms. Kuo, and is described as held for investment purposes. Future company filings may clarify if this ownership level changes over time or if any strategic transactions emerge involving this block.

Beneficial ownership 25,349,500 ordinary shares Shares beneficially owned by the reporting persons
Ownership percentage 33.34% Portion of Jyong Biotech ordinary shares represented by 25,349,500 shares
Shares outstanding 76,027,667 ordinary shares Issuer’s outstanding ordinary shares as of April 24, 2026
Acquisition funds $5,760,075 Aggregate amount used by Perfect Minds to acquire the reported shares
Par value $0.00001 per share Par value of Jyong Biotech ordinary shares
Event date 06/16/2025 Date of event requiring the Schedule 13D filing
beneficially own financial
"the Reporting Persons beneficially owns 25,349,500 ordinary shares of the Issuer"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
sole dispositive power financial
"Perfect Minds: sole voting power over 25,349,500 Ordinary Shares; sole dispositive power over 25,349,500 Ordinary Shares"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
pecuniary interest financial
"disclaims beneficial ownership of the securities reported herein except to the extent of its or her pecuniary interest therein"
family discretionary trust financial
"The Innovation Trust, a family discretionary trust established under the laws of Hong Kong"
Schedule 13D regulatory
"If the filing person has previously filed a statement on Schedule 13G to report the acquisition"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
Includes 25,349,500 Ordinary Shares being held by Perfect Minds Co., Ltd. a Seychelles company ("Perfect Minds"). Perfect Minds is a wholly owned subsidiary of Innovation Global Group Limited, a BVI company ("IGGL"). IGGL is a wholly owned subsidiary of the Innovation Trust, a family discretionary trust for which Unity Trust Limited acts as professional trustee. Ms. Kuo Fu-Feng is the settlor of The Innovation Trust and serves as the sole director of Perfect Minds and as the Chief Executive Officer and Chairwoman of the Board of Directors of the issuer. For the avoidance of doubt, the Reporting Persons expressly disclaim that they constitute a "group" within the meaning of Section 13(d)(3) except to the extent expressly stated herein. The percentage set forth in row (13) is based on the Issuer's 76,027,667 Ordinary Shares outstanding on April 24, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
Includes 25,349,500 Ordinary Shares being held by Perfect Minds Co., Ltd. a Seychelles company ("Perfect Minds"). Perfect Minds is a wholly owned subsidiary of Innovation Global Group Limited, a BVI company ("IGGL"). IGGL is a wholly owned subsidiary of the Innovation Trust, a family discretionary trust for which Unity Trust Limited acts as professional trustee. Ms. Kuo Fu-Feng is the settlor of The Innovation Trust and serves as the sole director of Perfect Minds and as the Chief Executive Officer and Chairwoman of the Board of Directors of the issuer. For the avoidance of doubt, the Reporting Persons expressly disclaim that they constitute a "group" within the meaning of Section 13(d)(3) except to the extent expressly stated herein. The percentage set forth in row (13) is based on the Issuer's 76,027,667 Ordinary Shares outstanding on April 24, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
Includes 25,349,500 Ordinary Shares being held by Perfect Minds Co., Ltd. a Seychelles company ("Perfect Minds"). Perfect Minds is a wholly owned subsidiary of Innovation Global Group Limited, a BVI company ("IGGL"). IGGL is a wholly owned subsidiary of the Innovation Trust, a family discretionary trust for which Unity Trust Limited acts as professional trustee. Ms. Kuo Fu-Feng is the settlor of The Innovation Trust and serves as the sole director of Perfect Minds and as the Chief Executive Officer and Chairwoman of the Board of Directors of the issuer. For the avoidance of doubt, the Reporting Persons expressly disclaim that they constitute a "group" within the meaning of Section 13(d)(3) except to the extent expressly stated herein. The percentage set forth in row (13) is based on the Issuer's 76,027,667 Ordinary Shares outstanding on April 24, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
Includes 25,349,500 Ordinary Shares being held by Perfect Minds Co., Ltd. a Seychelles company ("Perfect Minds"). Perfect Minds is a wholly owned subsidiary of Innovation Global Group Limited, a BVI company ("IGGL"). IGGL is a wholly owned subsidiary of he Innovation Trust, a family discretionary trust for which Unity Trust Limited acts as professional trustee. Ms. Kuo Fu-Feng is the settlor of The Innovation Trust and serves as the sole director of Perfect Minds and as the Chief Executive Officer and Chairwoman of the Board of Directors of the issuer. For the avoidance of doubt, the Reporting Persons expressly disclaim that they constitute a "group" within the meaning of Section 13(d)(3) except to the extent expressly stated herein. The percentage set forth in row (13) is based on the Issuer's 76,027,667 Ordinary Shares outstanding on April 24, 2026.


SCHEDULE 13D


Perfect Minds Co., Ltd
Signature:/s/ Kuo Fu-Feng
Name/Title:Kuo Fu-Feng, Director
Date:04/24/2026
Innovation Global Group Limited
Signature:/s/ Choa Kin Wai
Name/Title:CHOA Kin Wai, Director of Top Goal Management Limited, the Sole Director of Innovation Global Group Limited
Date:04/24/2026
Unity Trust Limited as trustee of The Innovation Trust
Signature:/s/ Choa Kin Wai
Name/Title:Choa Kin Wai, Director
Date:04/24/2026
Ms. Kuo Fu-Feng
Signature:/s/ Kuo Fu-Feng
Name/Title:Kuo Fu-Feng, Self
Date:04/24/2026

FAQ

How many Jyong Biotech (MENS) shares do the reporting persons beneficially own?

The reporting persons beneficially own 25,349,500 ordinary shares of Jyong Biotech. This position is held directly by Perfect Minds Co., Ltd., with indirect ownership through Innovation Global Group Limited and The Innovation Trust, forming a significant single-holder investment in the company.

What percentage of Jyong Biotech (MENS) is held by the reporting group?

The filing states that 25,349,500 ordinary shares represent 33.34% of Jyong Biotech’s ordinary shares. This percentage is calculated based on 76,027,667 outstanding ordinary shares of the company as of April 24, 2026, indicating a large minority stake.

Who ultimately controls the reported Jyong Biotech (MENS) shareholding?

Perfect Minds Co., Ltd. directly holds the shares, but Ms. Kuo Fu‑Feng has sole voting and dispositive power. She is settlor of The Innovation Trust, sole director of Perfect Minds, and serves as Jyong Biotech’s Chief Executive Officer and Chairwoman, concentrating decision authority over this stake.

How were the Jyong Biotech (MENS) shares acquired by Perfect Minds?

The securities reported were acquired by Perfect Minds using funds totaling approximately $5,760,075. These funds were provided to Perfect Minds by Ms. Kuo Fu‑Feng specifically for acquiring the ordinary shares, indicating direct financial support from the principal individual behind the trust structure.

What is the relationship between Perfect Minds and Innovation Global Group in the Jyong Biotech (MENS) filing?

Perfect Minds Co., Ltd. is a Seychelles holding company that directly owns the Jyong Biotech shares and is wholly owned by Innovation Global Group Limited. Innovation Global Group is itself wholly owned by The Innovation Trust, creating a layered holding structure above the direct share ownership.

Does the Jyong Biotech (MENS) Schedule 13D state any specific corporate plans?

The reporting persons state they hold Jyong Biotech ordinary shares for investment purposes. Aside from the information described, they indicate no present plans or intentions related to the range of corporate actions listed under Item 4, such as mergers, reclassifications, or significant asset transactions.